{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:38:56Z","timestamp":1772271536503,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-89771-x","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T18:29:46Z","timestamp":1739298586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Biochemical response to neoadjuvant hormonal therapy predicts long-term prostate cancer survival outcomes after high-dose-rate brachytherapy with external beam radiotherapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Tomoyuki","family":"Makino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyuki","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yaegashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Shigehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Nohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"89771_CR1","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy, F. C. et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N. Engl. J. Med. 388, 1547\u20131558. https:\/\/doi.org\/10.1056\/NEJMoa2214122 (2023).","journal-title":"N. Engl. J. Med."},{"key":"89771_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","volume":"8","author":"DP Dearnaley","year":"2007","unstructured":"Dearnaley, D. P. et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 8, 475\u2013487. https:\/\/doi.org\/10.1016\/S1470-2045(07)70143-2 (2007).","journal-title":"Lancet Oncol."},{"key":"89771_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","volume":"70","author":"DA Kuban","year":"2008","unstructured":"Kuban, D. A. et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70, 67\u201374. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.06.054 (2008).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"89771_CR4","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.ijrobp.2008.02.073","volume":"72","author":"A Al-Mamgani","year":"2008","unstructured":"Al-Mamgani, A. et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 72, 980\u2013988. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.02.073 (2008).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"89771_CR5","first-page":"1723","volume":"35","author":"T Makino","year":"2015","unstructured":"Makino, T., Mizokami, A. & Namiki, M. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute. Anticancer Res. 35, 1723\u20131728 (2015).","journal-title":"Anticancer Res."},{"key":"89771_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.brachy.2017.01.006","volume":"16","author":"H Ishiyama","year":"2017","unstructured":"Ishiyama, H. et al. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium. Brachytherapy 16, 503\u2013510. https:\/\/doi.org\/10.1016\/j.brachy.2017.01.006 (2017).","journal-title":"Brachytherapy"},{"key":"89771_CR7","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.ijrobp.2016.12.013","volume":"97","author":"Y Yoshioka","year":"2017","unstructured":"Yoshioka, Y. et al. Nationwide, multicenter, retrospective study on high-dose-rate brachytherapy as monotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 97, 952\u2013961. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.12.013 (2017).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"89771_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.21873\/anticanres.13137","volume":"39","author":"T Makino","year":"2019","unstructured":"Makino, T. et al. Health-related quality of life and toxicity after single-fraction high-dose-rate brachytherapy with external beam radiotherapy for localized and locally advanced prostate cancer. Anticancer Res. 39, 477\u2013486. https:\/\/doi.org\/10.21873\/anticanres.13137 (2019).","journal-title":"Anticancer Res."},{"key":"89771_CR9","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1007\/s10147-021-02023-6","volume":"26","author":"T Makino","year":"2021","unstructured":"Makino, T. et al. The effectiveness of high-dose-rate brachytherapy with external beam radiotherapy for clinically locally advanced and node-positive prostate cancer: long-term results of a retrospective study. Int. J. Clin. Oncol. 26, 2310\u20132317. https:\/\/doi.org\/10.1007\/s10147-021-02023-6 (2021).","journal-title":"Int. J. Clin. Oncol."},{"key":"89771_CR10","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1007\/s10147-023-02359-1","volume":"28","author":"S Kadena","year":"2023","unstructured":"Kadena, S. et al. The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and external beam radiation. Int. J. Clin. Oncol. 28, 1092\u20131100. https:\/\/doi.org\/10.1007\/s10147-023-02359-1 (2023).","journal-title":"Int. J. Clin. Oncol."},{"key":"89771_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.radonc.2017.12.025","volume":"127","author":"L Astrom","year":"2018","unstructured":"Astrom, L., Grusell, E., Sandin, F., Turesson, I. & Holmberg, L. Two decades of high dose rate brachytherapy with external beam radiotherapy for prostate cancer. Radiother. Oncol. 127, 81\u201387. https:\/\/doi.org\/10.1016\/j.radonc.2017.12.025 (2018).","journal-title":"Radiother. Oncol."},{"key":"89771_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.radonc.2018.10.013","volume":"132","author":"TB Wedde","year":"2019","unstructured":"Wedde, T. B. et al. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort. Radiother. Oncol. 132, 211\u2013217. https:\/\/doi.org\/10.1016\/j.radonc.2018.10.013 (2019).","journal-title":"Radiother. Oncol."},{"key":"89771_CR13","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1080\/0284186X.2021.1953706","volume":"60","author":"M Hjalm-Eriksson","year":"2021","unstructured":"Hjalm-Eriksson, M. et al. High rate of local control and cure at 10 years after treatment of prostate cancer with external beam radiotherapy and high-dose-rate brachytherapy: a single centre experience. Acta Oncol. 60, 1301\u20131307. https:\/\/doi.org\/10.1080\/0284186X.2021.1953706 (2021).","journal-title":"Acta Oncol."},{"key":"89771_CR14","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.ijrobp.2020.11.008","volume":"110","author":"IC Hsu","year":"2021","unstructured":"Hsu, I. C. et al. Long-term results of NRG oncology\/RTOG 0321: A phase II trial of combined high dose rate brachytherapy and external beam radiation therapy for adenocarcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 110, 700\u2013707. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.11.008 (2021).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"89771_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","volume":"154","author":"PJ Hoskin","year":"2021","unstructured":"Hoskin, P. J., Rojas, A. M., Ostler, P. J., Bryant, L. & Lowe, G. J. Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results. Radiother. Oncol. 154, 214\u2013219. https:\/\/doi.org\/10.1016\/j.radonc.2020.09.047 (2021).","journal-title":"Radiother. Oncol."},{"key":"89771_CR16","volume-title":"The TNM Classification of Malignant Tumours","author":"J Brierley","year":"2016","unstructured":"Brierley, J., Gospodarowicz, M. & Wittekind, C. The TNM Classification of Malignant Tumours 8th edn. (Wiley-Blackwell, 2016).","edition":"8"},{"key":"89771_CR17","unstructured":"Schaeffer, E. M. et al. Prostate Cancer, Version 1.2025, NCCN Clinical Practice Guidelines in Oncology. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"89771_CR18","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s11604-020-01023-2","volume":"38","author":"T Sakurai","year":"2020","unstructured":"Sakurai, T. et al. Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-\/very high-risk prostate cancer: A dosimetric analysis of toxicity. Jpn. J. Radiol. 38, 1197\u20131208. https:\/\/doi.org\/10.1007\/s11604-020-01023-2 (2020).","journal-title":"Jpn. J. Radiol."},{"key":"89771_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.brachy.2011.09.008","volume":"11","author":"Y Yamada","year":"2012","unstructured":"Yamada, Y. et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 11, 20\u201332. https:\/\/doi.org\/10.1016\/j.brachy.2011.09.008 (2012).","journal-title":"Brachytherapy"},{"key":"89771_CR20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.brachy.2019.03.002","volume":"18","author":"MJ Xu","year":"2019","unstructured":"Xu, M. J. et al. Single-fraction brachytherapy as monotherapy for early-stage prostate cancer: The UCSF experience. Brachytherapy 18, 470\u2013476. https:\/\/doi.org\/10.1016\/j.brachy.2019.03.002 (2019).","journal-title":"Brachytherapy"},{"key":"89771_CR21","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach 3rd","year":"2006","unstructured":"Roach, M. 3rd. et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 65, 965\u2013974. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.04.029 (2006).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"89771_CR22","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","volume":"294","author":"AL Zietman","year":"2005","unstructured":"Zietman, A. L. et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294, 1233\u20131239. https:\/\/doi.org\/10.1001\/jama.294.10.1233 (2005).","journal-title":"JAMA"},{"key":"89771_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","volume":"103","author":"PJ Hoskin","year":"2012","unstructured":"Hoskin, P. J. et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother. Oncol. 103, 217\u2013222. https:\/\/doi.org\/10.1016\/j.radonc.2012.01.007 (2012).","journal-title":"Radiother. Oncol."},{"key":"89771_CR24","doi-asserted-by":"publisher","first-page":"e180039","DOI":"10.1001\/jamaoncol.2018.0039","volume":"4","author":"JM Michalski","year":"2018","unstructured":"Michalski, J. M. et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol. 4, e180039\u2013e180039. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0039 (2018).","journal-title":"JAMA Oncol."},{"key":"89771_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/s0360-3016(99)00406-x","volume":"46","author":"CR King","year":"2000","unstructured":"King, C. R., DiPetrillo, T. A. & Wazer, D. E. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, imrt, and brachytherapy from radiobiologic models. Int. J. Radiat. Oncol. Biol. Phys. 46, 165\u2013172. https:\/\/doi.org\/10.1016\/s0360-3016(99)00406-x (2000).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"89771_CR26","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/s0360-3016(98)00438-6","volume":"43","author":"DJ Brenner","year":"1999","unstructured":"Brenner, D. J. & Hall, E. J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 43, 1095\u20131101. https:\/\/doi.org\/10.1016\/s0360-3016(98)00438-6 (1999).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"89771_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/s0360-3016(01)02664-5","volume":"52","author":"DJ Brenner","year":"2002","unstructured":"Brenner, D. J. et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha\/beta ratio), similar to late-responding normal tissue. Int. J. Radiat. Oncol. Biol. Phys. 52, 6\u201313. https:\/\/doi.org\/10.1016\/s0360-3016(01)02664-5 (2002).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"89771_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.clon.2019.11.003","volume":"32","author":"GC Morton","year":"2020","unstructured":"Morton, G. C. & Alrashidi, S. M. High dose rate brachytherapy in high-risk localised disease\u2014why do anything else?. Clin. Oncol. (R. Coll. Radiol.) 32, 163\u2013169. https:\/\/doi.org\/10.1016\/j.clon.2019.11.003 (2020).","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"89771_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ctrv.2016.03.016","volume":"46","author":"T Zilli","year":"2016","unstructured":"Zilli, T., Dal Pra, A., Kountouri, M. & Miralbell, R. Prognostic value of biochemical response to neoadjuvant androgen deprivation before external beam radiotherapy for prostate cancer: A systematic review of the literature. Cancer Treat. Rev. 46, 35\u201341. https:\/\/doi.org\/10.1016\/j.ctrv.2016.03.016 (2016).","journal-title":"Cancer Treat. Rev."},{"key":"89771_CR30","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.radonc.2008.11.013","volume":"91","author":"L Sullivan","year":"2009","unstructured":"Sullivan, L. et al. Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother. Oncol. 91, 232\u2013236. https:\/\/doi.org\/10.1016\/j.radonc.2008.11.013 (2009).","journal-title":"Radiother. Oncol."},{"key":"89771_CR31","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/iju.14045","volume":"26","author":"A Sekiguchi","year":"2019","unstructured":"Sekiguchi, A. et al. Relationship between the dose to the bulbomembranous urethra and stricture after high dose-rate brachytherapy for prostate cancer: Matched-pair analysis. Int. J. Urol. 26, 938\u2013939. https:\/\/doi.org\/10.1111\/iju.14045 (2019).","journal-title":"Int. J. Urol."},{"key":"89771_CR32","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.urology.2013.08.036","volume":"83","author":"S Herschorn","year":"2014","unstructured":"Herschorn, S., Elliott, S., Coburn, M., Wessells, H. & Zinman, L. SIU\/ICUD consultation on urethral strictures: posterior urethral stenosis after treatment of prostate cancer. Urology 83, S59-70. https:\/\/doi.org\/10.1016\/j.urology.2013.08.036 (2014).","journal-title":"Urology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89771-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89771-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89771-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T18:29:49Z","timestamp":1739298589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89771-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89771"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89771-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5118"}}